靶向疗法联合化疗对转移性结直肠癌患者的肿瘤标志物、预后影响研究  

A Study on the Lmpact of Targeted Therapy Combined with Chemotherapy on Tumor Markers and Prognosis in Patients with Metastatic Colorectal Cancer

作　　者：林淑君 苏慧娜 刘丽敏 LIN Shujun;SU Huina;LIU Limin(Department of Oncology,Zhangzhou Hospital Affiliated to Fujian Medical University,Zhangzhou 363000,China;Department of Clinical Laboratory,Zhangzhou Hospital Affiliated to Fujian Medical University,Zhangzhou 363000,China)

机构地区：[1]福建医科大学附属漳州市医院肿瘤内科,漳州363000 [2]福建医科大学附属漳州市医院检验科,漳州363000

出　　处：《中国医药指南》2024年第30期96-98,共3页Guide of China Medicine

摘　　要：目的 探讨靶向疗法联合化疗对转移性结直肠癌(mCRC)患者的肿瘤标志物表达及预后的影响。方法 将2021年1月至2023年6月我院肿瘤科诊治的60例mCRC患者纳入研究中,根据治疗方法不同分成研究组(靶向疗法联合化疗)、对照组(单一化疗),均为30例;治疗4个周期后测定血清肿瘤标志物甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原125(CA125)的水平,评估总有效率,随访掌握生存情况和不良反应发生率。结果 治疗后研究组患者血清AFP、CEA、CA125、CA199水平均低于对照组(P <0.05)。研究组总有效率高于对照组(P <0.05)。在治疗期间,研究组肝功能损伤、肠道反应及皮疹的发生率相对高于对照组(P <0.05),骨髓抑制的发生率无统计学意义(P> 0.05)。通过随访,研究组的生存期、无疾病进展生存期均长于对照组(P <0.05)。结论 靶向疗法联合化疗治疗m CRC有良好效果,能有效降低肿瘤标志物,改善患者预后,但相对会增加不良反应。Objective To explore the effect of targeted therapy combined with chemotherapy on the expression of tumor markers and prognosis in patients with metastatic colorectal cancer(mCRC).Methods Sixty mCRC patients diagnosed and treated in the oncology department of our hospital from January 2021 to June 2023 were included in the study.They were divided into a study group(targeted therapy combined with chemotherapy)and a control group(single chemotherapy) based on different treatment methods,with 30 cases in each group.After 4 cycles of treatment,the levels of serum tumor markers alpha fetoprotein(AFP),carcinoembryonic antigen(CEA),and carbohydrate antigen 125(CA125) were measured to evaluate the overall effective rate.Follow up was conducted to assess survival and incidence of adverse reactions.Results After treatment,the levels of AFP,CEA,CA125 and CA199 in the study group were lower than those in the control group(P<0.05).The total effective rate of the study group was higher than that of the control group(P< 0.05).During the treatment period,the incidence of liver function damage,intestinal reactions,and rash in the study group was relatively higher than that in the control group(P<0.05),and there was no significant difference in the incidence of bone marrow suppression(P>0.05).Through follow-up,the survival and progression free survival of the study group were longer than those of the control group(P<0.05).Conclusions Targeted therapy combined with chemotherapy has a good effect on mCRC,which can effectively reduce tumor markers and improve patient prognosis,but relatively increase adverse reactions.

关 键 词：靶向疗法 西妥昔单抗 化疗 转移性直肠癌 肿瘤标志物 生存期 

分 类 号：R735.37[医药卫生—肿瘤]